Last updated: 11/04/2026 12:00:23

A pivotal clinical study to investigate efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage MASHZENITH-1

GSK study ID
301160
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Trial status
Recruiting
Recruiting
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
Trial description: The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
Primary purpose:
Treatment
Trial design:
Parallel
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52

Timeframe: At Week 52

Proportion of participants experiencing resolution of steatohepatitis reading and no worsening of MASH CRN fibrosis score at Week 52

Timeframe: At Week 52

Time from randomization to an adjudicated composite liver-related clinical outcome

Timeframe: From Randomization (Day 1) to 48 months

Secondary outcomes:

Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severity

Timeframe: At Week 52 and at Month 48

Number of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity

Timeframe: At Week 52 and at Month 48

Number of participants with Grade 3 and Grade 4 laboratory abnormalities

Timeframe: At Week 52 and at Month 48

Proportion of participants experiencing resolution of steatohepatitis on overall histopathological reading and improvement in liver fibrosis of >=1 stage at Week 52

Timeframe: At Week 52

Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of Steatohepatitis at Month 48

Timeframe: At Month 48

Proportion of participants experiencing improvement in fibrosis by >=2 stage and no worsening of Steatohepatitis at Week 52 and Month 48

Timeframe: At Week 52 and Month 48

Proportion of participants experiencing resolution of steatohepatitis reading and no worsening of MASH CRN score at Month 48

Timeframe: At Month 48

Absolute change from Baseline in vibration-controlled transient elastography-liver stiffness measurement (VCTE-LSM)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Percent change from Baseline in VCTE-LSM

Timeframe: Baseline (Day 1), Week 52 and Month 48

Absolute change from Baseline in controlled attenuation parameter (CAP) scores

Timeframe: Baseline (Day 1), Week 52 and Month 48

Percent change from Baseline in CAP scores

Timeframe: Baseline (Day 1), Week 52 and Month 48

Proportion of participants achieving Change from Baseline in VCTE-LSM >=30 percent (%) at Week 52 and Month 48

Timeframe: Baseline (Day 1), Week 52 and Month 48

Absolute change from Baseline in magnetic resonance elastography (MRE) scores

Timeframe: Baseline (Day 1), Week 52 and Month 48

Percent change from Baseline in MRE Score

Timeframe: Baseline (Day 1), Week 52 and Month 48

Absolute change from Baseline in Enhanced Liver Fibrosis (ELF) Score

Timeframe: Baseline (Day 1), Week 52 and Month 48

Percent change from Baseline in ELF Score

Timeframe: Baseline (Day 1), Week 52 and Month 48

Proportion of participants experiencing improvement in ELF score of >=0.5

Timeframe: At Week 52 and Month 48

Absolute change from Baseline in hepatic fat fraction (HFF) by MRI-derived proton density fat fraction (PDFF)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Percent change from Baseline in HFF by MRI-PDFF

Timeframe: Baseline (Day 1), Week 52 and Month 48

Absolute change from Baseline in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (International units per liter)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Percent change from Baseline in ALT and AST (International units per liter)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Absolute change from Baseline in ALT and AST ratio (ALT/AST)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Percent change from Baseline in ALT and AST ratio (ALT/AST)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Proportion of participants experiencing ALT and HFF normalization at Week 52 and Month 48

Timeframe: At Week 52 and Month 48

Proportion of participants experiencing HFF <=5% at Week 52 and Month 48

Timeframe: At Week 52 and Month 48

Change from Baseline in glycated hemoglobin (HbA1c) (Percentage of HbA1c) in participants with Type 2 Diabetes Mellitus (T2DM)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Change from Baseline in body weight (kilograms)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Change from Baseline in fasting total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)- cholesterol, and triglycerides (Millimoles per liter)

Timeframe: Baseline (Day 1), Week 52 and Month 48

Proportion of participants with antidrug and antiFGF21 antibody (ADA)

Timeframe: At Week 52 and Month 48

Change from Baseline in Chronic Liver Disease Questionnaire-Nonalcoholic Steatohepatitis (CLDQ-NASH) in domain and total score

Timeframe: Baseline (Day 1), Week 52 and Month 48

Change from Baseline in Short Form-36 (SF-36) component and domain scores at Week 52 and Month 48

Timeframe: Baseline (Day 1), Week 52 and Month 48

Serum drug Concentration of efimosfermin alfa

Timeframe: Up to Month 48

Interventions:
Drug: Efimosfermin alfa
Drug: Placebo
Enrollment:
1200
Primary completion date:
2028-27-07
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Non-alcoholic Fatty Liver Disease
Product
Not applicable
Collaborators
Not applicable
Study date(s)
October 2025 to December 2031
Type
Interventional
Phase
3

Participation criteria

Sex
Female & Male
Age
18 - 75 Years
Accepts healthy volunteers
No
  • 1. Able and willing to understand and sign a written informed consent form that must be obtained prior to the initiation of study procedures
  • 2. Age >=18 and <=75 years at enrollment
  • 1. Contraindication or ineligibility for percutaneous liver biopsy
  • 2. ALT or AST >=5 x upper limit of normal (ULN)

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Miami, FL, United States, 33156-7397
Status
Recruiting
Location
GSK Investigational Site
Waco, TX, United States, 76712
Status
Recruiting
Location
GSK Investigational Site
Ocala, FL, United States, 34471
Status
Recruiting
Location
GSK Investigational Site
Saint Louis, MO, United States, 63141
Status
Recruiting
Location
GSK Investigational Site
San Antonio, TX, United States, 78215
Status
Recruiting
Location
GSK Investigational Site
Hialeah, FL, United States, 33016
Status
Recruiting
Location
GSK Investigational Site
Manassas, Virginia, United States, 20110
Status
Recruiting
Location
GSK Investigational Site
DeSoto, TX, United States, 75115
Status
Recruiting
Location
GSK Investigational Site
Palmetto Bay, FL, United States, 33157
Status
Recruiting
Location
GSK Investigational Site
Los Angeles, CA, United States, 90057-3507
Status
Recruiting
Location
GSK Investigational Site
Maitland, FL, United States, 32751
Status
Recruiting
Location
GSK Investigational Site
Van Nuys, CA, United States, 91405
Status
Recruiting
Location
GSK Investigational Site
Austin, TX, United States, 78704
Status
Recruiting
Location
GSK Investigational Site
Springboro, OH, United States, 45066
Status
Recruiting
Location
GSK Investigational Site
Austin, TX, United States, 78759
Status
Recruiting
Location
GSK Investigational Site
Richmond, TX, United States, 77406
Status
Recruiting
Location
GSK Investigational Site
Tomball, TX, United States, 77375-3332
Status
Recruiting
Location
GSK Investigational Site
Cape Coral, FL, United States, 33914
Status
Recruiting
Location
GSK Investigational Site
Akron, OH, United States, 44320
Status
Recruiting
Location
GSK Investigational Site
Seabrook, TX, United States, 77586
Status
Recruiting
Location
GSK Investigational Site
Santa Maria, CA, United States, 93458
Status
Recruiting
Location
GSK Investigational Site
Arcadia, CA, United States, 91006
Status
Recruiting
Location
GSK Investigational Site
Lakeland, FL, United States, 33803
Status
Recruiting
Location
GSK Investigational Site
Waco, TX, United States, 76710
Status
Recruiting
Location
GSK Investigational Site
New York, NY, United States, 10036
Status
Recruiting
Location
GSK Investigational Site
Inverness, FL, United States, 34452
Status
Recruiting
Location
GSK Investigational Site
Seattle, WA, United States, 98105
Status
Recruiting
Location
GSK Investigational Site
West Jordan, UT, United States, 84088
Status
Recruiting
Location
GSK Investigational Site
Brownsville, TX, United States, 78526
Status
Recruiting
Location
GSK Investigational Site
Sugar Land, TX, United States, 77479
Status
Recruiting
Location
GSK Investigational Site
Morehead City, NC, United States, 28557
Status
Recruiting
Location
GSK Investigational Site
Miami, FL, United States, 33155
Status
Recruiting
Location
GSK Investigational Site
San Antonio, TX, United States, 78229
Status
Recruiting
Location
GSK Investigational Site
East Syracuse, NY, United States, 13057
Status
Recruiting
Location
GSK Investigational Site
Jacksonville, FL, United States, 32216
Status
Recruiting
Location
GSK Investigational Site
Covina, CA, United States, 91723
Status
Recruiting
Location
GSK Investigational Site
Dallas, TX, United States, 75243-1921
Status
Recruiting
Location
GSK Investigational Site
Miami, FL, United States, 33184
Status
Recruiting
Location
GSK Investigational Site
Kissimmee, FL, United States, 34744
Status
Recruiting
Location
GSK Investigational Site
Topeka, KS, United States, 66606
Status
Recruiting
Location
GSK Investigational Site
Miami Lakes, FL, United States, 33014
Status
Recruiting
Location
GSK Investigational Site
Boynton Beach, FL, United States, 33435-5610
Status
Recruiting
Location
GSK Investigational Site
Miami, FL, United States, 33144
Status
Recruiting
Location
GSK Investigational Site
New York, NY, United States, 10036-4103
Status
Recruiting
Location
GSK Investigational Site
Bellaire, TX, United States, 77401
Status
Recruiting
Location
GSK Investigational Site
Chattanooga, TN, United States, 37421
Status
Recruiting
Location
GSK Investigational Site
Springfield, IL, United States, 62703-2403
Status
Recruiting
Location
GSK Investigational Site
Montclair, CA, United States, 91763
Status
Recruiting
Location
GSK Investigational Site
Riverdale, GA, United States, 30274-2615
Status
Recruiting
Location
GSK Investigational Site
Colorado Springs, CO, United States, 80907
Status
Recruiting
Location
GSK Investigational Site
Clermont, FL, United States, 34711
Status
Recruiting
Location
GSK Investigational Site
Sarasota, FL, United States, 34201
Status
Recruiting
Location
GSK Investigational Site
Marrero, LA, United States, 70072
Status
Recruiting
Location
GSK Investigational Site
Homestead, FL, United States, 33033
Status
Recruiting
Location
GSK Investigational Site
Fort Myers, FL, United States, 33912
Status
Recruiting
Location
GSK Investigational Site
Irving, Texas, United States, 75061
Status
Recruiting
Location
GSK Investigational Site
Heidelberg, VIC, Australia, 3084
Status
Recruiting
Location
GSK Investigational Site
Tucson, AZ, United States, 85712
Status
Recruiting
Location
GSK Investigational Site
San Antonio, TX, United States, 78209
Status
Recruiting
Location
GSK Investigational Site
Chandler, AZ, United States, 85224-4711
Status
Recruiting
Location
GSK Investigational Site
Fayetteville, NC, United States, 28304
Status
Recruiting
Location
GSK Investigational Site
Las Vegas, NV, United States, 89106
Status
Recruiting
Location
GSK Investigational Site
Austin, TX, United States, 78757-8066
Status
Recruiting
Location
GSK Investigational Site
Miami, FL, United States, 33173
Status
Recruiting
Location
GSK Investigational Site
Arlington, TX, United States, 76012
Status
Recruiting
Location
GSK Investigational Site
San Diego, CA, United States, 92120-5244
Status
Recruiting
Location
GSK Investigational Site
Kansas City, MO, United States, 64131
Status
Recruiting
Location
GSK Investigational Site
Pokfulam, Hong Kong
Status
Recruiting
Location
GSK Investigational Site
Broadmeadow, NSW, Australia, 2292
Status
Recruiting
Location
GSK Investigational Site
San Juan, PR, United States, 00927
Status
Recruiting
Location
GSK Investigational Site
Bastrop, LA, United States, 71220-5035
Status
Recruiting
Location
GSK Investigational Site
Kyoto, Japan, 602-8566
Status
Recruiting
Location
GSK Investigational Site
Chia-Yi, Taiwan, 600
Status
Recruiting
Location
GSK Investigational Site
Kaohsiung, Taiwan, 83301
Status
Recruiting
Location
GSK Investigational Site
Wellington, New Zealand, 6021
Status
Recruiting
Location
GSK Investigational Site
Riyadh, Unmapped, 11472
Status
Recruiting
Location
GSK Investigational Site
Quebec, QC, Canada, G1N 4V3
Status
Recruiting
Location
GSK Investigational Site
Yokohama, Japan, 236-0004
Status
Recruiting
Location
GSK Investigational Site
Musashino, Japan, 180-8610
Status
Recruiting
Location
GSK Investigational Site
Kanagawa, Japan, 215-0026
Status
Recruiting
Location
GSK Investigational Site
Folsom, California, United States, 95630
Status
Recruiting
Location
GSK Investigational Site
Little Rock, AR, United States, 72211
Status
Recruiting
Location
GSK Investigational Site
Westlake, OH, United States, 44145-1493
Status
Recruiting
Location
GSK Investigational Site
Gifu, Japan, 503-8502
Status
Recruiting
Location
GSK Investigational Site
Houston, TX, United States, 77004
Status
Recruiting
Location
GSK Investigational Site
Marietta, GA, United States, 30060-8948
Status
Recruiting
Location
GSK Investigational Site
Norfolk, VA, United States, 23502
Status
Recruiting
Location
GSK Investigational Site
Seoul, Unmapped, 06591
Status
Recruiting
Location
GSK Investigational Site
Sliven, Bulgaria
Status
Recruiting
Location
GSK Investigational Site
Jerusalem, Israel, 91031
Status
Recruiting
Location
GSK Investigational Site
Myslowice, Poland, 41-400
Status
Recruiting
Location
GSK Investigational Site
Taipei, Taiwan, 110
Status
Recruiting
Location
GSK Investigational Site
Sofia, Bulgaria, 1510
Status
Recruiting
Location
GSK Investigational Site
Leipzig, Sachsen, Germany, 04103
Status
Recruiting
Location
GSK Investigational Site
Durham, NC, United States, 27705-4674
Status
Recruiting
Location
GSK Investigational Site
Taipei, Taiwan, 10041
Status
Recruiting
Location
GSK Investigational Site
Woolloongabba, QLD, Australia, 4102
Status
Recruiting
Location
GSK Investigational Site
Kagoshima, Japan, 890-8520
Status
Recruiting
Location
GSK Investigational Site
Gunma, Japan, 370-0829
Status
Recruiting
Location
GSK Investigational Site
St Louis, MO, United States, 63123
Status
Recruiting
Location
GSK Investigational Site
Seoul, Unmapped, 03080
Status
Recruiting
Location
GSK Investigational Site
Paris, France, 75013
Status
Recruiting
Location
GSK Investigational Site
Seoul, Unmapped, 03722
Status
Recruiting
Location
GSK Investigational Site
Milano, Italy, 20122
Status
Recruiting
Location
GSK Investigational Site
A CoruNa, Spain, 15006
Status
Recruiting
Location
GSK Investigational Site
Tel Aviv, Israel, 69710
Status
Recruiting
Location
GSK Investigational Site
Clichy, France, 92110
Status
Recruiting
Location
GSK Investigational Site
Tokyo, Japan, 113-8519
Status
Recruiting
Location
GSK Investigational Site
Panagyurishte, Bulgaria, 4500
Status
Recruiting
Location
GSK Investigational Site
Suwon-si, Unmapped, 16499
Status
Recruiting
Location
GSK Investigational Site
Saga, Japan, 849-8501
Status
Recruiting
Location
GSK Investigational Site
Gifu, Japan, 500-8513
Status
Recruiting
Location
GSK Investigational Site
Glen Burnie, MD, United States, 21061
Status
Recruiting
Location
GSK Investigational Site
Pasadena, TX, United States, 77505
Status
Recruiting
Location
GSK Investigational Site
Richmond, VA, United States, 23249
Status
Recruiting
Location
GSK Investigational Site
Kagawa, Japan, 761-0793
Status
Recruiting
Location
GSK Investigational Site
Kelowna, BC, Canada, V1Y 1Z9
Status
Recruiting
Location
GSK Investigational Site
Auckland, New Zealand, 2025
Status
Recruiting
Location
GSK Investigational Site
Tucson, AZ, United States, 85712-2822
Status
Recruiting
Location
GSK Investigational Site
Surat, Gujarat, India, 395010
Status
Recruiting
Location
GSK Investigational Site
Surat, India, 395009
Status
Recruiting
Location
GSK Investigational Site
Rehovot, Israel, 76100
Status
Recruiting
Location
GSK Investigational Site
Haifa, Israel, 3436212
Status
Recruiting
Location
GSK Investigational Site
Ciudad Real, Spain, 13700
Status
Recruiting
Location
GSK Investigational Site
Daegu-si, Unmapped, 42601
Status
Recruiting
Location
GSK Investigational Site
Seongnam-si Gyeonggi-do, Unmapped, 13620
Status
Recruiting
Location
GSK Investigational Site
Bucheon-si Kyunggi-do 14584, Unmapped, 14584
Status
Recruiting
Location
GSK Investigational Site
Nagpur, India, 440010
Status
Recruiting
Location
GSK Investigational Site
Yamaguchi, Japan, 750-0061
Status
Recruiting
Location
GSK Investigational Site
Aichi, Japan, 480-1195
Status
Recruiting
Location
GSK Investigational Site
Brasilia, Distrito Federal, Brazil, 70200-730
Status
Recruiting
Location
GSK Investigational Site
Wyoming, MI, United States, 49519
Status
Recruiting
Location
GSK Investigational Site
Tainan, Taiwan, 704
Status
Recruiting
Location
GSK Investigational Site
Christchurch, New Zealand, 8011
Status
Recruiting
Location
GSK Investigational Site
Botucatu, SAO PAULO, Brazil, 18618-970
Status
Recruiting
Location
GSK Investigational Site
Gent, Belgium, 9000
Status
Recruiting
Location
GSK Investigational Site
Buenos Aires, Argentina
Status
Recruiting
Location
GSK Investigational Site
BrasIlia, Brazil, 71625-009
Status
Recruiting
Location
GSK Investigational Site
Graz, Steiermark, Austria, 8036
Status
Recruiting
Location
GSK Investigational Site
CLERMONT-FERRAND CEDEX 1, France, 63000
Status
Recruiting
Location
GSK Investigational Site
Pusan, Unmapped, 49241
Status
Recruiting
Location
GSK Investigational Site
Osaka, Japan, 564-0013
Status
Recruiting
Location
GSK Investigational Site
Saitama, Japan, 350-0495
Status
Recruiting
Location
GSK Investigational Site
Daegu, Unmapped, 700-721
Status
Recruiting
Location
GSK Investigational Site
Sofia, Bulgaria, 1606
Status
Recruiting
Location
GSK Investigational Site
Beijing, China, 100050
Status
Recruiting
Location
GSK Investigational Site
Soffia, Bulgaria, 1407
Status
Recruiting
Location
GSK Investigational Site
Beer Sheva, Israel, 84001
Status
Recruiting
Location
GSK Investigational Site
Tauranga, New Zealand, 3112
Status
Recruiting
Location
GSK Investigational Site
Sofia, Bulgaria, 1202
Status
Recruiting
Location
GSK Investigational Site
Plovdiv, Bulgaria, 4000
Status
Recruiting
Location
GSK Investigational Site
Kanagawa, Japan, 259-1143
Status
Recruiting
Location
GSK Investigational Site
Niigata, Japan, 940-8653
Status
Recruiting
Location
GSK Investigational Site
Maroochydore, QLD, Australia, 4558
Status
Recruiting
Location
GSK Investigational Site
Petach Tikva, Israel, 4941492
Status
Recruiting
Location
GSK Investigational Site
Naharyia, Israel, 11111
Status
Recruiting
Location
GSK Investigational Site
Indianapolis, IN, United States, 46202
Status
Recruiting
Location
GSK Investigational Site
Barcelona, Spain, 08035
Status
Recruiting
Location
GSK Investigational Site
Rozzano, Italy, 20089
Status
Recruiting
Location
GSK Investigational Site
Seoul, Unmapped, 06351
Status
Recruiting
Location
GSK Investigational Site
Hong Kong, Hong Kong
Status
Recruiting
Location
GSK Investigational Site
Dammam, Unmapped, 34212
Status
Recruiting
Location
GSK Investigational Site
Fukuoka, Japan, 830-0011
Status
Recruiting
Location
GSK Investigational Site
Fukuoka, Japan, 814-0180
Status
Recruiting
Location
GSK Investigational Site
Osaka, Japan, 558-8558
Status
Recruiting
Location
GSK Investigational Site
Barcelona, Spain, 08023
Status
Recruiting
Location
GSK Investigational Site
Seoul, Unmapped, 08308
Status
Recruiting
Location
GSK Investigational Site
Holon, Israel, 5822012
Status
Recruiting
Location
GSK Investigational Site
Lyon, France, 69004
Status
Recruiting
Location
GSK Investigational Site
Lodz, Poland, 90-302
Status
Recruiting
Location
GSK Investigational Site
Chengdu, China, 610072
Status
Recruiting
Location
GSK Investigational Site
Ashkelon, Israel, 7830604
Status
Recruiting
Location
GSK Investigational Site
Seongnam-si, Unmapped, 463-712
Status
Recruiting
Location
GSK Investigational Site
Ludhiana, India, 141001
Status
Recruiting
Location
GSK Investigational Site
Zhenjiang, China, 212021
Status
Recruiting
Location
GSK Investigational Site
Roma, Roma, Italy, 00128
Status
Recruiting
Location
GSK Investigational Site
Kanagawa, Japan, 216-8511
Status
Recruiting
Location
GSK Investigational Site
Kolkata, India, 700020
Status
Recruiting
Location
GSK Investigational Site
Hamilton, ON, Canada, L8N 1Y2
Status
Recruiting
Location
GSK Investigational Site
Nara, Japan, 634-8522
Status
Recruiting
Location
GSK Investigational Site
Rennes, France, 35033
Status
Recruiting
Location
GSK Investigational Site
Ramat Gan, Israel, 52621
Status
Recruiting
Location
GSK Investigational Site
AlcorcOn, Spain, 28922
Status
Recruiting
Location
GSK Investigational Site
Trabzon, Turkey, 61187
Status
Recruiting
Location
GSK Investigational Site
Foggia, Italy, 71122
Status
Recruiting
Location
GSK Investigational Site
Roma, RM, Italy, 00168
Status
Recruiting
Location
GSK Investigational Site
Sao Caetano do Sul, São Paulo, Brazil, 09530-700
Status
Recruiting
Location
GSK Investigational Site
Athens, Greece, 10676
Status
Recruiting
Location
GSK Investigational Site
Barcelona, Spain, 08041
Status
Recruiting
Location
GSK Investigational Site
Footscray, VIC, Australia, 3011
Status
Recruiting
Location
GSK Investigational Site
Katowice, Poland, 40-600
Status
Recruiting
Location
GSK Investigational Site
Stara Zagora, Bulgaria, 6004
Status
Recruiting
Location
GSK Investigational Site
Nanjing, China, 210003
Status
Recruiting
Location
GSK Investigational Site
Jeddah, Unmapped, 21423
Status
Recruiting
Location
GSK Investigational Site
Ningbo, China, 315000
Status
Recruiting
Location
GSK Investigational Site
Pune, India, 411004
Status
Recruiting
Location
GSK Investigational Site
Sofia, Bulgaria, 1618
Status
Recruiting
Location
GSK Investigational Site
Shanghai, China, 200050
Status
Recruiting
Location
GSK Investigational Site
Iwate, Japan, 028-3695
Status
Recruiting
Location
GSK Investigational Site
London, United Kingdom, SE5 9NU
Status
Recruiting
Location
GSK Investigational Site
Porto Alegre, Brazil, 90160-093
Status
Recruiting
Location
GSK Investigational Site
Plovdiv, Bulgaria, 4002
Status
Recruiting
Location
GSK Investigational Site
Angers, France, 49100
Status
Recruiting
Location
GSK Investigational Site
Villejuif, France, 94804
Status
Recruiting
Location
GSK Investigational Site
London, United Kingdom, E1 1FR
Status
Recruiting
Location
GSK Investigational Site
Istanbul, Fatih, Turkey, 34093
Status
Recruiting
Location
GSK Investigational Site
Melbourne, VIC, Australia, 3004
Status
Recruiting
Location
GSK Investigational Site
Milano, MI, Italy, 20122
Status
Recruiting
Location
GSK Investigational Site
Firenze, Italy, 50134
Status
Recruiting
Location
GSK Investigational Site
SEVILLA, Sevilla, Spain, 41013
Status
Recruiting
Location
GSK Investigational Site
Chapel Hill, NC, United States, 27599
Status
Recruiting
Location
GSK Investigational Site
Ehime, Japan, 791-0295
Status
Recruiting
Location
GSK Investigational Site
London, United Kingdom, SW10 9NH
Status
Recruiting
Location
GSK Investigational Site
Vitacura, Santiago, Chile, 7630000
Status
Recruiting
Location
GSK Investigational Site
Dammam, Unmapped, 31444
Status
Recruiting
Location
GSK Investigational Site
Charleston, SC, United States, 29425
Status
Recruiting
Location
GSK Investigational Site
Liaocheng, China, 252000
Status
Recruiting

Study documents

No study documents available.

Results overview

Study Results yet to be posted

Recruitment status
Recruiting
Actual primary completion date
Not applicable
Actual study completion date
Not applicable

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website